Literature DB >> 1689630

Clinical significance of a multiple biomarker assay in patients with lung cancer. A study with logistic regression analysis.

C Lombardi1, G F Tassi, G Pizzocolo, F Donato.   

Abstract

The relative usefulness of a combination of some tumor markers, such as CEA, AFP, ferritin and NSE for the diagnosis of lung cancer was assessed by multiple logistic analysis. Serum concentration of these markers was determined in 68 patients with lung cancer (50 with NSCLC and 18 with SCLC, in 68 patients with benign lung disease and 75 normal control subjects. Ferritin proved to be the most useful in diagnosing both NSCLC and SCLC, while NSE was found to be of some help in diagnosing SCLC only. The multiple marker panel proved to be more sensitive and specific than any single marker in discriminating lung cancer from normal control tissue, but it was of limited value in discriminating malignant from benign lung disease. The results of the present study would suggest that the panel of investigated tumor markers is not of great help for the early diagnosis of lung cancer.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1689630     DOI: 10.1378/chest.97.3.639

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

1.  Lung cancer-associated auto-antibodies measured using seven amino acid peptides in a diagnostic blood test for lung cancer.

Authors:  Nada H Khattar; Sarah P Coe-Atkinson; Arnold J Stromberg; James R Jett; Edward A Hirschowitz
Journal:  Cancer Biol Ther       Date:  2010-08-18       Impact factor: 4.742

2.  Using protein microarray as a diagnostic assay for non-small cell lung cancer.

Authors:  Li Zhong; Giovanna E Hidalgo; Arnold J Stromberg; Nada H Khattar; James R Jett; Edward A Hirschowitz
Journal:  Am J Respir Crit Care Med       Date:  2005-08-18       Impact factor: 21.405

3.  Neuron-specific enolase as a marker of brain metastasis in patients with small-cell lung carcinoma.

Authors:  M van de Pol; A Twijnstra; G P ten Velde; P P Menheere
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

4.  A re-evaluation of squamous cell carcinoma antigen (SCC) as a serum marker for non-small cell lung cancer.

Authors:  Katsunori Kagohashi; Hiroaki Satoh; Hiroichi Ishikawa; Morio Ohtsuka; Kiyohisa Sekizawa
Journal:  Med Oncol       Date:  2007-10-30       Impact factor: 3.064

5.  The relationship between tumor markers and pulmonary embolism in lung cancer.

Authors:  Wei Xiong; Yunfeng Zhao; Mei Xu; Jian Guo; Bigyan Pudasaini; Xueling Wu; Jinming Liu
Journal:  Oncotarget       Date:  2017-06-20

6.  The Marker State Space (MSS) method for classifying clinical samples.

Authors:  Brian P Fallon; Bryan Curnutte; Kevin A Maupin; Katie Partyka; Sunguk Choi; Randall E Brand; Christopher J Langmead; Waibhav Tembe; Brian B Haab
Journal:  PLoS One       Date:  2013-06-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.